Loading video...
Video Failed to Load
Big Pharma keeps using R&D costs to justify high launch prices even after peer-reviewed research found no association between the two. The argument persists because it protects profits and blocks reform. Rob Burgess follows the receipts.
102,084 views • 1 month ago •via X (Twitter)
0 Comments
No comments available
Comments from the original post will appear here


